A research collaboration has been agreed between Dualsystems Biotech AG, a biotechnology company based in Schlieren in the canton of Zurich, and aTyr Pharma from San Diego, California. According to a press release, together they plan to work on the identification of ten new therapeutic targets. Targets are biomolecules to which active substances can bind. Dualsystems will use its proprietary receptor screening technology to identify and validate up to ten new target receptors for tRNA synthetases by 2025.
According to a press release, aTyr currently has more than 200 patents protecting the company’s own scientific library of extracellular tRNA synthetase protein fragments. This library comprises fragments from all 20 tRNA synthetases present in human cells. It focuses on the fragments that are most likely to be therapeutically useful based on known links to human diseases. Identifying specific receptor targets for the various tRNA synthetase fragments is an important step in this process. Dualsystems’ receptor screening technology will be used for this.
Dualsystems Biotech’s CEO Paul Helbing stated that the company is very pleased to work in collaboration with aTyr to maximize the capabilities of its innovative proprietary screening technology and internal expertise to help potentially generate new therapeutic opportunities from their unique discovery platform.
Sanjay S. Shukla, President and CEO of aTyr, commented: “We look forward to discoveries from this collaboration as a way to potentially accelerate drug discovery efforts and identify new drugs from our platform.”
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space